This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.
Beilstein J. Org. Chem. 2013, 9, 717–732, doi:10.3762/bjoc.9.82
Graphical Abstract
Figure 1: FDA-approved riluzole (1) and other ALS drugs currently in phase III clinical trials (2–6).
Figure 2: Riluzole (left) and prodrugs developed by McDonnell et al. [11].
Figure 3: Neurotransmitters N-acetyl-aspartyl glutamate (NAAG, top) and D-serine (bottom).
Figure 4: Thiopyridazines developed to increase EAAT2 protein levels.
Figure 5: Compounds shown to reduce SOD1 expression.
Figure 6: Families of compounds (named in italics) capable of reducing SOD1-induced cellular toxicity and mut...
Figure 7: Compounds identified by Nowak and co-workers [37] in silico that selectively bind SOD1 over human plasm...
Figure 8: 4-Aminoquinolines developed by Cassel and co-workers [43] for disruption of oligonucleotide/TDP-43 bind...
Figure 9: Cu(II)(atsm), an example of a Cu(II)(btsc) copper complex.
Figure 10: Pharmacological inducers of autophagy.
Figure 11: Compounds used to evaluate the effects of trophic factors on ALS disease progression.
Figure 12: Compounds identified as neuroprotective.
Figure 13: Compounds developed to reduce oxidative stress and inflammation.
Figure 14: Probes used to elucidate the roles of distinct gene-expression profiles in ALS patients.
Figure 15: Targets of potential therapeutics: This diagram illustrates the physiological targets of each compo...